ACE-031
An investigational broad activin-receptor ligand trap that increased lean mass but was discontinued after vascular safety findings.
- Human evidencen/a
- Animal evidencen/a
- Mechanisticn/a
- Safety knowledgen/a
- Editorial confidence5/5
Evidence Snapshot
- Overall
- 3/5Moderate certainty (with caveats)
- Human
- 3/5Multiple human studies
- Animal
- 0/5None identified
- In-vitro
- 0/5None identified
- Safety
- 3/5Reasonable safety characterisation
Scientific identity
- Peptide family
- Activin type IIB receptor ligand trap
- Entity class
- Investigational peptide
- Alternative names
- RamaterceptActRIIB-IgG1 Fc fusion protein
Developed as a soluble activin type IIB receptor fused to an IgG1 Fc domain to bind myostatin and related ligands and increase skeletal-muscle mass.
Proposed Mechanisms
- not-yet-documentedpending-editorial-review
- Activin type IIB ligand trapping →established
Reported / Studied Uses
- Muscle massEvidence · moderate
- Muscle growthEvidence · moderate
Human Evidence
Early trials showed increased lean mass and muscle volume. A Duchenne muscular dystrophy trial was stopped early because of epistaxis and telangiectasia, and functional benefit was not established.
Animal Evidence
Animal studies show substantial increases in skeletal-muscle mass through blockade of myostatin and related ligands.
Safety & Unknowns
Regulatory Status
| Country | Status | Notes |
|---|
Community Observations
References
- No verified references linked yet. Editors will add primary sources.
Full Disclaimer
This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.
Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.
Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.
Explore further
from the knowledge graph- Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial2017 · randomized_placebo_controlled_trial
- A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers2013 · randomized_placebo_controlled_phase_1_study